Related Experiment Video
Updated: May 4, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Telbivudine: a hepatitis B-specific antiviral
1Department of Gastroenterology and Hepatology, National University Hospital, Department of Medicine, Yong Yoo Lin School of Medicine, National University of Singapore, Singapore and Principal Investigator, Immunovirology group, Centre for Molecular Medicine, Co-Principal Investigator, Institute of Molecular and Cell Biology, Biopolis, Singapore. mdclimsg@nus.edu.sg.
Telbivudine demonstrates superior efficacy over lamivudine for treating chronic hepatitis B virus (HBV) infection. This potent polymerase inhibitor offers improved viral DNA reduction and reduced resistance, establishing it as a valuable therapeutic option.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Telbivudine is a potent, specific inhibitor of the hepatitis B virus (HBV) polymerase.
- It has completed Phase III trials and received worldwide licensing.
Purpose of the Study:
- To evaluate the efficacy of telbivudine compared to existing treatments for chronic hepatitis B.
- To assess telbivudine's effectiveness in both Hepatitis B e antigen-positive and -negative patients.
Main Methods:
- Phase III clinical trials comparing telbivudine with lamivudine.
- Studies on switching from lamivudine to telbivudine in suboptimal responders.
- Comparative analysis with adefovir for HBV DNA reduction.
- Multivariate analysis to identify predictors of long-term outcomes.
Main Results:
- Telbivudine showed superior efficacy to lamivudine in therapeutic response, HBV DNA reduction, and resistance profiles over 2 years.
- Switching to telbivudine improved HBV DNA reduction at week 24 in lamivudine-suboptimal responders.
- Telbivudine demonstrated superiority over adefovir in HBV DNA reduction at week 24.
- Week 24 HBV DNA levels were the strongest predictor of 2-year outcomes.
Conclusions:
- Telbivudine is a highly effective treatment for chronic hepatitis B, offering significant advantages over lamivudine.
- Its efficacy in reducing viral load and resistance makes it a key addition to hepatitis B therapeutics.
- A 'hepatitis B roadmap' based on early viral load response is proposed for patient management.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retroviruses
Subviral Agents
Viruses with RNA Genomes